6.62
price up icon2.00%   0.13
after-market Dopo l'orario di chiusura: 6.62
loading
Precedente Chiudi:
$6.49
Aprire:
$6.34
Volume 24 ore:
236.38K
Relative Volume:
1.51
Capitalizzazione di mercato:
$377.00M
Reddito:
-
Utile/perdita netta:
$-66.86M
Rapporto P/E:
-5.5167
EPS:
-1.2
Flusso di cassa netto:
$-58.82M
1 W Prestazione:
+2.00%
1M Prestazione:
+9.78%
6M Prestazione:
+103.69%
1 anno Prestazione:
+28.54%
Intervallo 1D:
Value
$6.00
$6.73
Intervallo di 1 settimana:
Value
$6.00
$7.22
Portata 52W:
Value
$2.60
$7.77

Design Therapeutics Inc Stock (DSGN) Company Profile

Name
Nome
Design Therapeutics Inc
Name
Telefono
858-293-4900
Name
Indirizzo
6005 HIDDEN VALLEY ROAD, CARLSBAD
Name
Dipendente
57
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-10
Name
Ultimi documenti SEC
Name
DSGN's Discussions on Twitter

Confronta DSGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
DSGN
Design Therapeutics Inc
6.62 369.59M 0 -66.86M -58.82M -1.20
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-05-07 Aggiornamento Piper Sandler Neutral → Overweight
2023-11-14 Downgrade Piper Sandler Overweight → Neutral
2023-08-15 Downgrade RBC Capital Mkts Outperform → Sector Perform
2023-08-15 Downgrade SVB Securities Outperform → Market Perform
2023-08-15 Downgrade Wedbush Outperform → Neutral
2023-05-04 Aggiornamento Goldman Sell → Neutral
2022-06-10 Iniziato Wedbush Outperform
2022-05-02 Iniziato RBC Capital Mkts Outperform
2022-01-19 Iniziato Goldman Sell
2021-04-20 Iniziato Goldman Neutral
2021-04-20 Iniziato Piper Sandler Overweight
2021-04-20 Iniziato SVB Leerink Outperform
Mostra tutto

Design Therapeutics Inc Borsa (DSGN) Ultime notizie

pulisher
Oct 14, 2025

How to integrate Design Therapeutics Inc. into portfolio analysis toolsJuly 2025 News Drivers & Daily Technical Forecast Reports - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics - Yahoo Finance

Oct 14, 2025
pulisher
Oct 13, 2025

How Design Therapeutics Inc. stock reacts to global recession fearsTrade Analysis Summary & Safe Capital Allocation Plans - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Does Design Therapeutics Inc. fit your quant trading modelIndex Update & Risk Controlled Daily Trade Plans - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Is it time to cut losses on Design Therapeutics Inc.Analyst Downgrade & Risk Controlled Daily Plans - newser.com

Oct 12, 2025
pulisher
Oct 10, 2025

Published on: 2025-10-10 09:52:08 - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Leading vs lagging indicators on Design Therapeutics Inc. performanceJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is Design Therapeutics Inc. a candidate for recovery playJuly 2025 EndofMonth & Accurate Entry/Exit Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Design Therapeutics Inc. stock volume spike explainedJuly 2025 Short Interest & AI Optimized Trade Strategies - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Why Design Therapeutics Inc. stock is in analyst buy zone2025 Technical Overview & Low Drawdown Trading Strategies - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Design Therapeutics (NASDAQ:DSGN) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 09, 2025

Published on: 2025-10-09 02:15:05 - newser.com

Oct 09, 2025
pulisher
Oct 07, 2025

Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025 - Yahoo Finance

Oct 07, 2025
pulisher
Oct 06, 2025

Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ong - PharmiWeb.com

Oct 06, 2025
pulisher
Oct 06, 2025

Is Design Therapeutics Inc a good long term investmentInstitutional Buying Trends & Low Entry Investment Plans - earlytimes.in

Oct 06, 2025
pulisher
Oct 06, 2025

Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ongoing Clinical Trials, Market Dynamics, Patent AnalysisResearchAndMarkets.com - Business Wire

Oct 06, 2025
pulisher
Oct 06, 2025

Design Therapeutics Inc. recovery potential after sell offFed Meeting & Real-Time Chart Pattern Alerts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Should you hold or exit Design Therapeutics Inc. now2025 Technical Overview & Smart Investment Allocation Tips - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Top chart patterns to watch in Design Therapeutics Inc.2025 Price Targets & Free Verified High Yield Trade Plans - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5 - 富途牛牛

Oct 03, 2025
pulisher
Oct 03, 2025

Analyzing Design Therapeutics Inc. with multi timeframe chartsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Risk adjusted return profile for Design Therapeutics Inc. analyzedEarnings Performance Report & Stepwise Entry and Exit Trade Signals - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Why Design Therapeutics Inc. stock is a must watch in 2025Trade Signal Summary & Smart Swing Trading Alerts - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design - Business Wire

Oct 02, 2025
pulisher
Oct 02, 2025

Vector Science & Therapeutics Appoints Tabitha Hendren as Director, Engineering and Design - PR Newswire Canada

Oct 02, 2025
pulisher
Oct 01, 2025

Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Bausch + Lomb, Santen Pharmaceutical, and Trefoil Therapeutics, Actively Shaping the Competitive Landscape - 24matins.uk

Oct 01, 2025
pulisher
Sep 30, 2025

Design Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Low Cost Stock Picks - earlytimes.in

Sep 30, 2025

Design Therapeutics Inc Azioni (DSGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Capitalizzazione:     |  Volume (24 ore):